UT Southwestern Medical Center
Welcome,         Profile    Billing    Logout  
 859 Trials 
2237 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davis, Kathryn
NCT04649008: Localizing Epileptic Networks Using MRI and iEEG

Recruiting
1
290
US
3T Magnetic Resonance Imaging, 3T MRI, Intracranial electroencephalography recordings, Intracranial EEG recordings, 7T Magnetic Resonance Imaging, 7T MRI
University of Pennsylvania, Medical University of South Carolina
Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
02/26
02/26
Aberg, Judith
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
INSIGHT12, NCT04910269 / 2021-001663-24: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/26
08/26
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active, not recruiting
2
135
US
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
ViiV Healthcare
HIV Infections
11/24
01/29
NCT06741397: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Active, not recruiting
2
191
US
CAB LA, New formulation of CAB LA
ViiV Healthcare
HIV Infections
09/26
12/28
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Completed
1
17
US
MGD020, MGD014
MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
05/24
05/24
Powderly, John Mellors; William
NCT05431270: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Completed
1/2
93
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
03/25
03/25
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab, Nivolumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer
08/25
09/25
NCT05388435: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Terminated
1/2
15
US
SKL27969
SK Life Science, Inc.
Advanced Solid Tumor
03/24
03/24
NCT04875806: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Terminated
1/2
40
US
NC762
NextCure, Inc.
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
01/24
01/24
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
04/26
NCT06014658: Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting
1/2
130
US
Antibody-Drug Conjugate
MBrace Therapeutics
Cancer
07/26
11/26
KEYNOTE-B59, NCT04977453: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
GI-101, Pembrolizumab (KEYTRUDA®), KEYTRUDA®, Lenvatinib, Lenvima®, Local Radiotherapy, GI-101A
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma, Microsatellite Stable Colorectal Carcinoma, Merkel Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
10/25
10/26
XTX101-01, NCT04896697: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting
1/2
136
US
vilastobart (XTX101), Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
NCT05055609: Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Recruiting
1
85
US
TRE-515
Trethera
Solid Tumor, Adult, Oncology
12/26
06/27
NCT05118841: Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Recruiting
1
60
US
ZX-4081
Nanjing Zenshine Pharmaceuticals
Advanced Solid Tumor
05/23
05/24
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
NCT04417465: First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Active, not recruiting
1
101
Europe, Japan, US, RoW
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumors Cancer
05/26
05/26
NCT04777994: Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
10/26
10/26
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
PEEL-224-001, NCT05329103: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Recruiting
1
42
US
PEEL-224
Peel Therapeutics Inc
Advanced Solid Tumor
03/25
03/26
NCT05569057: A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Recruiting
1
100
US
SIM1811-03, SIM0235, TNFR2 monoclonal antibody
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
06/24
03/25
NCT05571969: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Suspended
1
40
US
2X-121 and dovitinib
Allarity Therapeutics, Amarex Clinical Research
Advanced Solid Tumors
10/24
03/25
NCT05115292: A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

Active, not recruiting
1
85
US
BJ-005
BJ Bioscience, Inc.
Advanced Solid Tumor or Lymphoma
10/24
10/25
CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed
1
42
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
03/25
03/25
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT05674526: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Active, not recruiting
1
30
US
WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion, Cetuximab - Cohort Expansion
Wugen, Inc.
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
09/25
06/26
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/25
11/25
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
NCT05989724: A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Recruiting
1
150
US
SON-DP
Qurgen Inc.
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
09/25
03/26
NCT00571389: A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Recruiting
N/A
1000
US
BioCytics, Inc.
Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
02/25
02/25
Miller, David S
NCT05850494: Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Completed
3
52
US
HFA MDI, Propellant in MDI, HFO MDI
AstraZeneca
Asthma
08/23
08/23
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Completed
3
2538
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
03/25
03/25
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
NCT03712605: Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Hourglass Jan 2023 - Dec 2023 : Results for stage I-III MCC that has been completely removed by surgery
Active, not recruiting
3
280
US
Best Practice, standard of care, standard therapy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
12/25
12/25
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
286
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/24
01/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
NRG-GY025, NCT05112601: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recruiting
2
90
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
04/26
04/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Active, not recruiting
2
119
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
05/26
05/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Completed
1/2
93
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
03/25
03/25
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
150
US, RoW
INX-315, Fulvestrant, faslodex, Abemaciclib, Verzenio
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT03272464: INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Terminated
1
1
US
Trametinib, Mekinist, Dabrafenib, Tafinlar, INCB039110, Itacitinib
Massachusetts General Hospital, Incyte Corporation
Melanoma
07/19
12/19
NCT03843957: Effectiveness and Implementation of mPATH-CRC

Completed
N/A
77145
US
mPATH-CRC, mPATH-Checkin, "high touch" Implementation strategy, "low touch" Implementation Strategy
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Colorectal Cancer, Cancer, Rectum Cancer, Colon Cancer
08/22
03/23
mPATH-Lung, NCT04083859: Digital Outreach Intervention for Lung Cancer Screening

Completed
N/A
26998
US
mPATH-Lung, Lung health video
Wake Forest University Health Sciences, University of North Carolina, Chapel Hill, National Cancer Institute (NCI)
Lung Cancer
09/23
09/24
NCT06241768: Feasibility of a Colorectal Cancer Screening Web App in Primary Care Patients

Not yet recruiting
N/A
1000
US
mPATH-CRC Web app
Digital Health Navigation Solutions, Inc, Wake Forest University Health Sciences, National Cancer Institute (NCI)
Colorectal Cancer Screening
05/24
06/24
NF1-TED, NCT06515860: Neurofibromatosis Type 1 Tumor Early Detection Study

Recruiting
N/A
1000
US
Liquid biopsy for MPNST development
David Miller
Neurofibromatosis Type 1, Neurofibromatosis 1, Plexiform Neurofibroma, Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumors, Atypical Neurofibroma
07/30
07/30
SAMBA, NCT04680611: Severe Asthma, MepolizumaB and Affect: Study

Recruiting
N/A
120
Europe
no study intervention. Patients receive standard clinical care, no intervention. observational study
University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University of Derby
Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression, Psychological Stress, Psychological Adjustment, Psychological Disorder, Psychosocial Problem, Psychosocial Stressor, Psychological, Emotions, Emotional Disorder, Emotional Dysfunction, Emotional Distress, Adjustment, Adjustment, Emotional, Coping Behavior
12/24
12/24
mPATH-Cloud, NCT06441487: for Colorectal Cancer Screening

Not yet recruiting
N/A
1000
US
Mobile Health Decision Support, mPATH™-Cloud, Usual care
UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Colorectal Cancer
07/27
01/29
NCT03141021: Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Recruiting
N/A
1050
Europe, Canada, Japan, US, RoW
Washington University School of Medicine, Boston's Children Hospital
Malignant Peripheral Nerve Sheath Tumors
04/53
04/53
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Aquino, Victor
MATCH, NCT06940570: Methadone as an Alternative Treatment for Children Underdoing HSCT

Not yet recruiting
3
60
US
PCA plus methadone (Experimental), Addition of methadone to standard of care (SOC), PCA Alone (SOC), Morphine OR Hydromorphone
University of Texas Southwestern Medical Center
Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
08/27
08/27
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Antithymocyte globulin rabbit ATG, Grafalon, Imtix, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Checkmark Pivotal data from ROCKstar trial in cGVHD
Jul 2021 - Jul 2021: Pivotal data from ROCKstar trial in cGVHD
Checkmark Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Jun 2021 - Jun 2021: Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Checkmark Follow-up data from ROCKstar trial for cGVHD at ASH
More
Terminated
2
159
US
Belumosudil (KD025), REZUROCK
Kadmon, a Sanofi Company
Chronic Graft-versus-host-disease
12/23
12/23
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
56
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Center for International Blood and Marrow Transplant Research
SCID
08/29
08/30
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT06393660: Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Available
N/A
US
CliniMACS® CD34 TCR Alpha/Beta
Victor Aquino
Transplant-Related Disorder, GVH - Graft Versus Host Reaction
 
 
NCT04678427: Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Recruiting
N/A
60
US
6 Minute Walk Functional Test, 6MWT, SIX MINUTE WALK, SIXMW1, Behavioral Intervention, Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments, Survey Administration, Timed Get Up and Go Test
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
12/25
12/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Lee, William M
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
INNOVATE, NCT04134260: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Recruiting
3
586
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Hormone Therapy, Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal Therapy, hormone treatment, Hormones, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
11/26
11/26
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, HOE-766, HOE766, ICI 123215, ICI-123215, ICI123215, S74 6766, S74-6766, S746766, Tiloryth, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY 25650, AY-25650, AY25650, CL 118532, CL-118,532, CL-118532, CL118532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
11/26
11/26
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2753
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, HOE-766, HOE766, ICI 123215, ICI-123215, ICI123215, S74 6766, S74-6766, S746766, Tiloryth, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Magnetic Resonance Elastography, MRE, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY 25650, AY-25650, AY25650, CL 118532, CL-118,532, CL-118532, CL118532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
GATEWAY, NCT04537377 / 2020-000963-22: A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Active, not recruiting
1/2
4
Europe, US
VTX-801
Vivet Therapeutics SAS
Wilson's Disease
12/24
06/29
PARADIGM, NCT05437458: Parkinson's Disease: Risk Assessment of Persistent Delirium and Its Management

Recruiting
N/A
217
Europe
Delirium (exposure)
Newcastle University
Parkinson Disease, Delirium in Old Age
08/25
09/25
HRN, NCT06057181: Helix Research Network

Recruiting
N/A
2000000
US
Exome sequencing
Helix, Inc, Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Nebraska Medicine - University of Nebraska Medical Center, Sanford Health, Cone Health, Renown Health, WakeMed Health & Hospitals, The Ohio State University Wexner Medical Center
Genetic Predisposition to Disease, Genetics Disease
09/31
09/36
Toto, Robert
NCT03982160: L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Recruiting
4
15
US
L-Arginine, Placebo
The University of Texas at Arlington
Chronic Kidney Disease
12/26
12/26
NCT03471117: Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Recruiting
4
28
US
Pioglitazone, Placebo
The University of Texas at Arlington, University of Texas, Southwestern Medical Center at Dallas
Chronic Kidney Diseases
04/25
04/25
NCT05033054: Effect of SGLT2i on Cardiovascular Biomarkers in Patients with Type 2 Diabetes and CKD Stage 3b-4

Active, not recruiting
N/A
28
US
SGLT2 inhibitor
University of Texas Southwestern Medical Center
Kidney Disease, Chronic, Diabetes
01/25
06/25
KPMP, NCT04334707: Kidney Precision Medicine Project

Recruiting
N/A
1000
US
Kidney Biopsy, Renal Biopsy, Laparotomy
University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan, Icahn School of Medicine at Mount Sinai, Brigham and Women's Hospital, Broad Institute, The Cleveland Clinic, Columbia University, European Molecular Biology Laboratory, Indiana University, Johns Hopkins University, Joslin Diabetes Center, Pacific Northwest National Laboratory, Princeton University, Stanford University, Ohio State University, University of California, San Diego, University of California, San Francisco, University of Pittsburgh, The University of Texas Health Science Center at San Antonio, University of Texas, Washington University School of Medicine, Yale University
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic
06/27
06/27
Evans, Patricia W
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
Cheng, Jonathan
NCT02994160: DExterous Hand Control Through Fascicular Targeting (DEFT) - (Human Subjects)

Recruiting
N/A
25
US
Fast electrode
University of Texas Southwestern Medical Center, Defense Advanced Research Projects Agency, Nerves Incorporated, Inc., Arizona State University, University of Minnesota
Amputation; Traumatic, Hand
12/25
12/25
Roehrborn, Claus
IMPACT, NCT04987892: Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

Recruiting
4
250
US
UroLift System, Tamsulosin Hydrochloride, Flomax
NeoTract, Inc.
BPH
05/25
10/25
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting
N/A
120
Europe, US
UroLift, Rezum
NeoTract, Inc.
Benign Prostatic Hyperplasia
05/25
12/25
NCT04658056: UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

Not yet recruiting
N/A
46
Europe
PROCEPT BioRobotics
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
01/22
02/22
Simone, Nicole L
NCT00026845: Comparison of Surgeries, With or Without Radiation Therapy, in Treating Women With Stage I or Stage II Breast Cancer

Active, not recruiting
3
237
US
axillary lymph node dissection, biopsy, therapeutic conventional surgery, radiation therapy
National Cancer Institute (NCI)
Breast Cancer
 
 
TAILOR RT, NCT03488693: Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Recruiting
3
2140
Canada, US
Radiation, No Radiation
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Breast Cancer
09/27
12/27
NCT02827370: CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer

Completed
N/A
26
US
Behavioral Dietary Intervention
Sidney Kimmel Cancer Center at Thomas Jefferson University
Breast Carcinoma
07/19
12/19
NCT06315296: An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Recruiting
N/A
60
US
Behavioral Dietary Intervention, Text Message-Based Navigation Intervention, Automated Text Message-Based Navigation, Text Message-Based Navigation, Internet-Based Intervention, Dietary Counseling and Surveillance, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Neurocognitive Assessment, Questionnaire Administration, Interview
Thomas Jefferson University
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
06/28
06/28
NCT04959474: Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Recruiting
N/A
80
US
Best Practice, best practice, standard of care, standard of care, standard therapy, Stereotactic Body Radiation Therapy, SABR, SBRT, SBRT, Stereotactic Ablative Body Radiation Therapy, stereotactic body radiation therapy, Resection, Resection, resection, Surgical Resection, SURGICAL RESECTION, Surgical Resection, Surgical Resection, Surgical Resection, Sentinel Lymph Node Biopsy, SENTINEL LYMPH NODE BIOPSY, sentinel lymph node biopsy, Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB, Dietary Intervention, Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition Interventions, Nutritional Interventions, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment
Thomas Jefferson University
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
11/25
01/26
NCT04074720: Prospective Breast Cancer Biospecimen Collection

Recruiting
N/A
200
US
Tissue Sample collection, Blood Sample Collection, Rectal Swab
Thomas Jefferson University
Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
08/28
08/28
Timmerman, Robert D
STABLE-MATES, NCT02468024: JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Recruiting
3
272
Europe, Canada, US, RoW
Lung Surgery, SR, Radiation therapy, SAbR
University of Texas Southwestern Medical Center
Non-Small Cell Lung Cancer
12/28
12/28
NCT03559556: Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning

Completed
1
14
US
CT angiography
University of Texas Southwestern Medical Center
Arteriovenous Malformations
09/21
06/24
NCT00992303: Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Recruiting
N/A
10000
US
biologic sample preservation procedure, medical chart review, questionnaire administration
University of Texas Southwestern Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
12/29
12/29
SRS, NCT02645487: Stereotactic Radiosurgery () Dose-Escalation Study for Brain Metastasis

Recruiting
N/A
135
US
Stereotactic Radiosurgery, SRS
University of Texas Southwestern Medical Center
Brain Neoplasms, Adult, Malignant
12/26
12/26
Euhus, David M
PROMISE, NCT02694809: The Study: Duavee in Women With DCIS

Completed
2
142
US
Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Northwestern University, National Cancer Institute (NCI), Pfizer, University of Chicago - Department for Cancer Research, University of California, San Francisco
Ductal Breast Carcinoma In Situ, Postmenopausal
06/24
06/24
Nguyen, Trung
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davis, Kathryn
NCT04649008: Localizing Epileptic Networks Using MRI and iEEG

Recruiting
1
290
US
3T Magnetic Resonance Imaging, 3T MRI, Intracranial electroencephalography recordings, Intracranial EEG recordings, 7T Magnetic Resonance Imaging, 7T MRI
University of Pennsylvania, Medical University of South Carolina
Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
02/26
02/26
Aberg, Judith
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
INSIGHT12, NCT04910269 / 2021-001663-24: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/26
08/26
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active, not recruiting
2
135
US
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
ViiV Healthcare
HIV Infections
11/24
01/29
NCT06741397: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Active, not recruiting
2
191
US
CAB LA, New formulation of CAB LA
ViiV Healthcare
HIV Infections
09/26
12/28
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Completed
1
17
US
MGD020, MGD014
MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
05/24
05/24
Powderly, John Mellors; William
NCT05431270: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Completed
1/2
93
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
03/25
03/25
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab, Nivolumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer
08/25
09/25
NCT05388435: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Terminated
1/2
15
US
SKL27969
SK Life Science, Inc.
Advanced Solid Tumor
03/24
03/24
NCT04875806: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Terminated
1/2
40
US
NC762
NextCure, Inc.
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
01/24
01/24
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
04/26
NCT06014658: Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting
1/2
130
US
Antibody-Drug Conjugate
MBrace Therapeutics
Cancer
07/26
11/26
KEYNOTE-B59, NCT04977453: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
GI-101, Pembrolizumab (KEYTRUDA®), KEYTRUDA®, Lenvatinib, Lenvima®, Local Radiotherapy, GI-101A
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma, Microsatellite Stable Colorectal Carcinoma, Merkel Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
10/25
10/26
XTX101-01, NCT04896697: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting
1/2
136
US
vilastobart (XTX101), Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
NCT05055609: Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Recruiting
1
85
US
TRE-515
Trethera
Solid Tumor, Adult, Oncology
12/26
06/27
NCT05118841: Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Recruiting
1
60
US
ZX-4081
Nanjing Zenshine Pharmaceuticals
Advanced Solid Tumor
05/23
05/24
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
NCT04417465: First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Active, not recruiting
1
101
Europe, Japan, US, RoW
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumors Cancer
05/26
05/26
NCT04777994: Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
10/26
10/26
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
PEEL-224-001, NCT05329103: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Recruiting
1
42
US
PEEL-224
Peel Therapeutics Inc
Advanced Solid Tumor
03/25
03/26
NCT05569057: A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Recruiting
1
100
US
SIM1811-03, SIM0235, TNFR2 monoclonal antibody
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
06/24
03/25
NCT05571969: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Suspended
1
40
US
2X-121 and dovitinib
Allarity Therapeutics, Amarex Clinical Research
Advanced Solid Tumors
10/24
03/25
NCT05115292: A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

Active, not recruiting
1
85
US
BJ-005
BJ Bioscience, Inc.
Advanced Solid Tumor or Lymphoma
10/24
10/25
CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed
1
42
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
03/25
03/25
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT05674526: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Active, not recruiting
1
30
US
WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion, Cetuximab - Cohort Expansion
Wugen, Inc.
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
09/25
06/26
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting
1
60
US, RoW
HCB101, SIRPα-Fc fusion protein
FBD Biologics Limited
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
05/25
11/25
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
NCT05989724: A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Recruiting
1
150
US
SON-DP
Qurgen Inc.
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
09/25
03/26
NCT00571389: A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Recruiting
N/A
1000
US
BioCytics, Inc.
Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
02/25
02/25
Miller, David S
NCT05850494: Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Completed
3
52
US
HFA MDI, Propellant in MDI, HFO MDI
AstraZeneca
Asthma
08/23
08/23
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Completed
3
2538
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
03/25
03/25
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
NCT03712605: Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Hourglass Jan 2023 - Dec 2023 : Results for stage I-III MCC that has been completely removed by surgery
Active, not recruiting
3
280
US
Best Practice, standard of care, standard therapy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
12/25
12/25
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
286
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/24
01/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
NRG-GY025, NCT05112601: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recruiting
2
90
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
04/26
04/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Active, not recruiting
2
119
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
05/26
05/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Completed
1/2
93
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
03/25
03/25
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
150
US, RoW
INX-315, Fulvestrant, faslodex, Abemaciclib, Verzenio
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT03272464: INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Terminated
1
1
US
Trametinib, Mekinist, Dabrafenib, Tafinlar, INCB039110, Itacitinib
Massachusetts General Hospital, Incyte Corporation
Melanoma
07/19
12/19
NCT03843957: Effectiveness and Implementation of mPATH-CRC

Completed
N/A
77145
US
mPATH-CRC, mPATH-Checkin, "high touch" Implementation strategy, "low touch" Implementation Strategy
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Colorectal Cancer, Cancer, Rectum Cancer, Colon Cancer
08/22
03/23
mPATH-Lung, NCT04083859: Digital Outreach Intervention for Lung Cancer Screening

Completed
N/A
26998
US
mPATH-Lung, Lung health video
Wake Forest University Health Sciences, University of North Carolina, Chapel Hill, National Cancer Institute (NCI)
Lung Cancer
09/23
09/24
NCT06241768: Feasibility of a Colorectal Cancer Screening Web App in Primary Care Patients

Not yet recruiting
N/A
1000
US
mPATH-CRC Web app
Digital Health Navigation Solutions, Inc, Wake Forest University Health Sciences, National Cancer Institute (NCI)
Colorectal Cancer Screening
05/24
06/24
NF1-TED, NCT06515860: Neurofibromatosis Type 1 Tumor Early Detection Study

Recruiting
N/A
1000
US
Liquid biopsy for MPNST development
David Miller
Neurofibromatosis Type 1, Neurofibromatosis 1, Plexiform Neurofibroma, Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumors, Atypical Neurofibroma
07/30
07/30
SAMBA, NCT04680611: Severe Asthma, MepolizumaB and Affect: Study

Recruiting
N/A
120
Europe
no study intervention. Patients receive standard clinical care, no intervention. observational study
University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University of Derby
Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression, Psychological Stress, Psychological Adjustment, Psychological Disorder, Psychosocial Problem, Psychosocial Stressor, Psychological, Emotions, Emotional Disorder, Emotional Dysfunction, Emotional Distress, Adjustment, Adjustment, Emotional, Coping Behavior
12/24
12/24
mPATH-Cloud, NCT06441487: for Colorectal Cancer Screening

Not yet recruiting
N/A
1000
US
Mobile Health Decision Support, mPATH™-Cloud, Usual care
UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Colorectal Cancer
07/27
01/29
NCT03141021: Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Recruiting
N/A
1050
Europe, Canada, Japan, US, RoW
Washington University School of Medicine, Boston's Children Hospital
Malignant Peripheral Nerve Sheath Tumors
04/53
04/53
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Aquino, Victor
MATCH, NCT06940570: Methadone as an Alternative Treatment for Children Underdoing HSCT

Not yet recruiting
3
60
US
PCA plus methadone (Experimental), Addition of methadone to standard of care (SOC), PCA Alone (SOC), Morphine OR Hydromorphone
University of Texas Southwestern Medical Center
Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
08/27
08/27
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Antithymocyte globulin rabbit ATG, Grafalon, Imtix, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Checkmark Pivotal data from ROCKstar trial in cGVHD
Jul 2021 - Jul 2021: Pivotal data from ROCKstar trial in cGVHD
Checkmark Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Jun 2021 - Jun 2021: Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Checkmark Follow-up data from ROCKstar trial for cGVHD at ASH
More
Terminated
2
159
US
Belumosudil (KD025), REZUROCK
Kadmon, a Sanofi Company
Chronic Graft-versus-host-disease
12/23
12/23
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
56
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Center for International Blood and Marrow Transplant Research
SCID
08/29
08/30
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT06393660: Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Available
N/A
US
CliniMACS® CD34 TCR Alpha/Beta
Victor Aquino
Transplant-Related Disorder, GVH - Graft Versus Host Reaction
 
 
NCT04678427: Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Recruiting
N/A
60
US
6 Minute Walk Functional Test, 6MWT, SIX MINUTE WALK, SIXMW1, Behavioral Intervention, Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments, Survey Administration, Timed Get Up and Go Test
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
12/25
12/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Lee, William M
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
INNOVATE, NCT04134260: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Recruiting
3
586
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Hormone Therapy, Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal Therapy, hormone treatment, Hormones, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
11/26
11/26
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, HOE-766, HOE766, ICI 123215, ICI-123215, ICI123215, S74 6766, S74-6766, S746766, Tiloryth, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY 25650, AY-25650, AY25650, CL 118532, CL-118,532, CL-118532, CL118532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
11/26
11/26
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2753
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, HOE-766, HOE766, ICI 123215, ICI-123215, ICI123215, S74 6766, S74-6766, S746766, Tiloryth, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Magnetic Resonance Elastography, MRE, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY 25650, AY-25650, AY25650, CL 118532, CL-118,532, CL-118532, CL118532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
GATEWAY, NCT04537377 / 2020-000963-22: A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Active, not recruiting
1/2
4
Europe, US
VTX-801
Vivet Therapeutics SAS
Wilson's Disease
12/24
06/29
PARADIGM, NCT05437458: Parkinson's Disease: Risk Assessment of Persistent Delirium and Its Management

Recruiting
N/A
217
Europe
Delirium (exposure)
Newcastle University
Parkinson Disease, Delirium in Old Age
08/25
09/25
HRN, NCT06057181: Helix Research Network

Recruiting
N/A
2000000
US
Exome sequencing
Helix, Inc, Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Nebraska Medicine - University of Nebraska Medical Center, Sanford Health, Cone Health, Renown Health, WakeMed Health & Hospitals, The Ohio State University Wexner Medical Center
Genetic Predisposition to Disease, Genetics Disease
09/31
09/36
Toto, Robert
NCT03982160: L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Recruiting
4
15
US
L-Arginine, Placebo
The University of Texas at Arlington
Chronic Kidney Disease
12/26
12/26
NCT03471117: Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Recruiting
4
28
US
Pioglitazone, Placebo
The University of Texas at Arlington, University of Texas, Southwestern Medical Center at Dallas
Chronic Kidney Diseases
04/25
04/25
NCT05033054: Effect of SGLT2i on Cardiovascular Biomarkers in Patients with Type 2 Diabetes and CKD Stage 3b-4

Active, not recruiting
N/A
28
US
SGLT2 inhibitor
University of Texas Southwestern Medical Center
Kidney Disease, Chronic, Diabetes
01/25
06/25
KPMP, NCT04334707: Kidney Precision Medicine Project

Recruiting
N/A
1000
US
Kidney Biopsy, Renal Biopsy, Laparotomy
University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan, Icahn School of Medicine at Mount Sinai, Brigham and Women's Hospital, Broad Institute, The Cleveland Clinic, Columbia University, European Molecular Biology Laboratory, Indiana University, Johns Hopkins University, Joslin Diabetes Center, Pacific Northwest National Laboratory, Princeton University, Stanford University, Ohio State University, University of California, San Diego, University of California, San Francisco, University of Pittsburgh, The University of Texas Health Science Center at San Antonio, University of Texas, Washington University School of Medicine, Yale University
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic
06/27
06/27
Evans, Patricia W
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
Cheng, Jonathan
NCT02994160: DExterous Hand Control Through Fascicular Targeting (DEFT) - (Human Subjects)

Recruiting
N/A
25
US
Fast electrode
University of Texas Southwestern Medical Center, Defense Advanced Research Projects Agency, Nerves Incorporated, Inc., Arizona State University, University of Minnesota
Amputation; Traumatic, Hand
12/25
12/25
Roehrborn, Claus
IMPACT, NCT04987892: Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

Recruiting
4
250
US
UroLift System, Tamsulosin Hydrochloride, Flomax
NeoTract, Inc.
BPH
05/25
10/25
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting
N/A
120
Europe, US
UroLift, Rezum
NeoTract, Inc.
Benign Prostatic Hyperplasia
05/25
12/25
NCT04658056: UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

Not yet recruiting
N/A
46
Europe
PROCEPT BioRobotics
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
01/22
02/22
Simone, Nicole L
NCT00026845: Comparison of Surgeries, With or Without Radiation Therapy, in Treating Women With Stage I or Stage II Breast Cancer

Active, not recruiting
3
237
US
axillary lymph node dissection, biopsy, therapeutic conventional surgery, radiation therapy
National Cancer Institute (NCI)
Breast Cancer
 
 
TAILOR RT, NCT03488693: Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Recruiting
3
2140
Canada, US
Radiation, No Radiation
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Breast Cancer
09/27
12/27
NCT02827370: CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer

Completed
N/A
26
US
Behavioral Dietary Intervention
Sidney Kimmel Cancer Center at Thomas Jefferson University
Breast Carcinoma
07/19
12/19
NCT06315296: An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Recruiting
N/A
60
US
Behavioral Dietary Intervention, Text Message-Based Navigation Intervention, Automated Text Message-Based Navigation, Text Message-Based Navigation, Internet-Based Intervention, Dietary Counseling and Surveillance, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Neurocognitive Assessment, Questionnaire Administration, Interview
Thomas Jefferson University
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
06/28
06/28
NCT04959474: Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Recruiting
N/A
80
US
Best Practice, best practice, standard of care, standard of care, standard therapy, Stereotactic Body Radiation Therapy, SABR, SBRT, SBRT, Stereotactic Ablative Body Radiation Therapy, stereotactic body radiation therapy, Resection, Resection, resection, Surgical Resection, SURGICAL RESECTION, Surgical Resection, Surgical Resection, Surgical Resection, Sentinel Lymph Node Biopsy, SENTINEL LYMPH NODE BIOPSY, sentinel lymph node biopsy, Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB, Dietary Intervention, Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition Interventions, Nutritional Interventions, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment
Thomas Jefferson University
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
11/25
01/26
NCT04074720: Prospective Breast Cancer Biospecimen Collection

Recruiting
N/A
200
US
Tissue Sample collection, Blood Sample Collection, Rectal Swab
Thomas Jefferson University
Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
08/28
08/28
Timmerman, Robert D
STABLE-MATES, NCT02468024: JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Recruiting
3
272
Europe, Canada, US, RoW
Lung Surgery, SR, Radiation therapy, SAbR
University of Texas Southwestern Medical Center
Non-Small Cell Lung Cancer
12/28
12/28
NCT03559556: Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning

Completed
1
14
US
CT angiography
University of Texas Southwestern Medical Center
Arteriovenous Malformations
09/21
06/24
NCT00992303: Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Recruiting
N/A
10000
US
biologic sample preservation procedure, medical chart review, questionnaire administration
University of Texas Southwestern Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
12/29
12/29
SRS, NCT02645487: Stereotactic Radiosurgery () Dose-Escalation Study for Brain Metastasis

Recruiting
N/A
135
US
Stereotactic Radiosurgery, SRS
University of Texas Southwestern Medical Center
Brain Neoplasms, Adult, Malignant
12/26
12/26
Euhus, David M
PROMISE, NCT02694809: The Study: Duavee in Women With DCIS

Completed
2
142
US
Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Northwestern University, National Cancer Institute (NCI), Pfizer, University of Chicago - Department for Cancer Research, University of California, San Francisco
Ductal Breast Carcinoma In Situ, Postmenopausal
06/24
06/24
Nguyen, Trung
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
 

Download Options